AML Hub

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit patients with newly diagnosed acute myeloid leukemia (AML)?In this interview, Roboz discusses key findings from a preliminary subgroup analysis of a phase Ib/II trial (NCT04086264), investigating the anti-CD123 antibody–drug conjugate pivekimab sunirine in combination with azacitidine and venetoclax, for ≥14 days or 28 days, in unfit patients with newly diagnosed CD123-positive AML. The primary endpoint was antileukemic activity, including complete remission (CR) and composite CR with incomplete hematologic recovery (CR/CRi) rates.This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How might the phase II PARADIGM trial data impact treatment decisions for newly diagnosed fit adults with acute myeloid leukemia (AML)?In this interview, Fathi discussed key findings from the open-label, randomized, phase II PARADIGM trial comparing azacitidine + venetoclax with conventional induction chemotherapy in functionally fit patients with newly diagnosed AML (NCT04801797). The primary endpoint was event-free survival.This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myeloid leukemia (AML)? Stein starts by discussing therapies approved for the treatment of IDH1-mutated (IDH1m) AML, including ivosidenib and olutasidenib, and supporting data. He then considers strategies in development for IDH-mutated AML, such as combining IDH1 inhibitors with venetoclax, before concluding with areas of interest for future research. Stein talks about the potential of IDH1 inhibitors in precursor states of myeloid malignancies, such as clonal cytopenia of undetermined significance (CCUS), and the aims of ongoing studies. This educational resource is independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical practice.” Searle summarizes the key considerations when using menin inhibitors in the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) in clinical practice, and her thoughts on key areas of interest looking forward. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussion featured contributions from Jessica Altman, Courtney DiNardo, Jeffrey Lancet, Roland Walter, and Joshua Zeidner.

The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for his thoughts on the topic “Integrating menin inhibitors into the treatment landscape of AML: Future directions”. Zeidner provides an overview of the latest clinical trial data on menin inhibitors in the treatment of NPM1-mutated or KMT2A-rearranged AML presented at the European Hematology Association 2025 Congress. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience addressed by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK; Gail J. Roboz, Weill Cornell Medicine, New York, US; and Ralph Hills, Connecticut, US.This independent educational activity is supported by Thermo Fisher Scientific. All content was developed independently by the faculty. The funder was allowed no influence on the content.

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz, Weill Cornell Medicine, New York, US, and Ralph Hills, Connecticut, US, where they consider how physicians and patients can communicate more clearly about mutation testing in AML.Roboz emphasized the importance of providing patients with clear, evidence-based information in a supportive manner, avoiding overwhelming technical language unless requested. She highlighted the need for open communication, encouraging questions, and creating a space where patients feel comfortable and empowered to make decisions. Hills enquired about the application of artificial intelligence (AI) in guiding treatment. Roboz explained that though online tools such as Google and AI may seem helpful, they can often mislead, and put forward that, regardless of how much information patients have, patients want to feel genuinely cared for and to know someone is looking out for them, while Craddock noted that AI could be useful in streamlining clinical trials and improving their accessibility for patients. Roboz identified the value of staying informed about the latest treatments, especially for serious conditions such as AML, and encouraged patients to ask critical questions about their disease, diagnosis, and treatment plan. Craddock added that collaboration among physicians is also crucial to ensure patients receive the best possible care.